Loading...
•
Jun 30, 2024
The Joint Q2 2024 Earnings Report
The Joint Corp. Q2 2024 financial results were reported, with revenue growing 3%, system-wide sales increasing 8%, and system-wide comp sales up 2% compared to Q2 2023.
Key Takeaways
The Joint Corp. reported a 3% increase in revenue to $30.3 million for Q2 2024. System-wide sales increased by 8% to $129.6 million, and system-wide comp sales grew by 2%. The company reported a net loss of $3.6 million, including $1.5 million in litigation expense and $1.4 million in loss on disposition or impairment. Adjusted EBITDA was $2.1 million.
Revenue grew 3% to $30.3 million compared to Q2 2023.
System-wide sales increased 8% to $129.6 million.
System-wide comp sales increased 2%.
The total clinic count reached 960 at June 30, 2024.
The Joint
The Joint
Forward Guidance
The company reiterated all elements of its guidance.
Positive Outlook
- System-wide sales are expected to be between $530 and $545 million, compared to $488.0 million in 2023.
- System-wide comp sales for all clinics open 13 months or more are expected to be in the mid-single digits in 2024.
- New franchised clinic openings, excluding the impact of refranchised clinics, are expected to be between 60 and 75, compared to 104 in 2023.